Cancer Cell Small Molecule Secretome Induces the Immune Checkpoint NKG2A and Dysfunction of Human CD8+ T Cells

Area of Science:

• Immunology
• Cancer Biology
• Cell Metabolism

Background:

• PD-1 blockade is approved for head and neck squamous cell carcinoma (HNSCC), but many patients show resistance.
• Increased NKG2A receptor expression on CD8+ T cells in HNSCC tumors suggests a role in immune evasion.
• Mechanisms driving NKG2A expression and its functional impact on T cells in the tumor microenvironment are not fully understood.

Purpose of the Study:

• To investigate the factors inducing NKG2A expression on CD8+ T cells in HNSCC.
• To elucidate the functional consequences of NKG2A induction on T cell metabolism and anti-tumor activity.
• To identify potential therapeutic targets for overcoming resistance to PD-1 blockade.

Main Methods:

• Incubation of CD8+ T cells with tumor-conditioned media (TCM) from HNSCC cell lines or ascites fluid.
• Analysis of NKG2A and other inhibitory receptor expression on T cells.
• Assessment of T cell mitochondrial respiration and metabolic function.
• Evaluation of T cell cytotoxicity and response to bispecific T cell engagers.

Main Results:

• TCM induced NKG2A and other inhibitory receptors on activated CD8+ T cells.
• The inducing factor in TCM is a small molecule resistant to boiling and filtration.
• T cell activation in TCM led to metabolic dysfunction, reduced mitochondrial respiration, and impaired cytotoxicity.
• TCM-treated T cells showed reduced killing of cancer cells, even with bispecific T cell engagers.

Conclusions:

• A small molecule secreted by HNSCC cells induces NKG2A expression, leading to CD8+ T cell dysfunction and metabolic impairment.
• These findings suggest novel therapeutic targets for HNSCC and biomarkers for predicting response to NKG2A blockade.
• The study provides a model for investigating T cell dysfunction and metabolic alterations in the tumor microenvironment.